Agilent Technologies Announces Board Leadership Changes and Appointment of New Director

Agilent Technologies, Inc. (NYSE: A) — Form 8-K Analysis: Leadership & Board Changes

1. Overview of the Filing

On September 8, 2026, Agilent Technologies, Inc. filed a Current Report on Form 8-K under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers) and Item 7.01 (Regulation FD Disclosure).

2. Key Governance Changes

• Retirement of Board Chair:

  • Boon Hwee Koh notified the company on September 2, 2026, of his decision to retire as Chairperson and member of the Board of Directors, effective September 4, 2026.
  • Mr. Koh's departure concludes 23 years of service on Agilent's Board.
  • The filing explicitly confirms that his retirement was not due to any disagreement with the company or the Board regarding operations, policies, or practices.

• Election of New Board Chair:

  • As disclosed in Exhibit 99.1, Dow R. Wilson (director since 2018 and current Chair of the Audit and Finance Committee) has been elected to succeed Mr. Koh as Chair of the Board, effective September 4, 2026.

• Appointment of New Director:

  • Glenn Boehnlein was appointed to fill the vacancy created by Mr. Koh’s retirement, effective September 4, 2026.
  • He will serve as a Class III director, with his term expiring at the 2027 Annual Meeting of Stockholders.
  • Mr. Boehnlein was appointed to both the Audit and Finance Committee and the Compensation Committee.
  • The Board designated Mr. Boehnlein as an independent director and an "audit committee financial expert" pursuant to Item 407(d)(5)(ii) of Regulation S-K.

3. Background of Appointee

• Glenn Boehnlein (Age 64):
  • Served as VP and CFO of Stryker Corporation from 2016 to 2025 during a 22-year career at Stryker.
  • Current Board and Audit Committee Chair at Inogen, Inc. (NASDAQ: INGN) and board member at Sutter Health.
  • Former Partner at Arthur Andersen LLP.

4. Compensation and Related Party Disclosures

• Mr. Boehnlein will receive standard non-employee director compensation (pro-rated for the current year) and enter into Agilent's standard director indemnification agreement.
• No Item 404(a) related-party transactions or family relationships exist.

5. Market & Trading Implications

• Significance: Low.
• The board transition represents an orderly and planned succession of governance leadership. The addition of Mr. Boehnlein brings senior financial and med-tech executive experience to Agilent's Board and Audit Committee.